VERV实时信号 | 通过Getagraph.com最大化利润

出售 113349 min ago

@ $12.71

发出时间: 15 Feb 2024 @ 03:22

回报率: -51.61%

上一信号: Feb 15 - 01:04

上一信号: 购买

回报率: 0.87 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 04:00):

Stats
今日成交量	928 599
平均成交量	1.32M
市值	483.08M
EPS	$0 ( 2024-03-07 )
下一个收益日期	( $-0.680 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.970
ATR14	$0.0100 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Nickerson Joan	Buy	3 315	Common Stock
2024-04-01	Nickerson Joan	Sell	3 315	Restricted Stock Units
2024-04-02	Nickerson Joan	Sell	1 514	Common Stock
2024-02-14	Ashe Andrew D.	Buy	150 000	Stock Option (right to buy)
2024-02-14	Ashe Andrew D.	Buy	36 000	Restricted Stock Units

INSIDER POWER
78.77
Last 97 transactions
Buy: 4 843 517 \| Sell: 1 394 833

音量相关性

長: -0.26 (neutral)

短: -0.24 (neutral)

Signal:(61.157) Neutral

Verve Therapeutics, Inc. 相关性

10 最正相关
SVOK	0.939
BIOL	0.915
ARVN	0.9
TSP	0.886
TIL	0.885
UK	0.884
YMAB	0.88
AVCT	0.879
FCACU	0.874
TFFP	0.873

10 最负相关
BOCH	-0.93
SHSP	-0.897
LMRK	-0.881
QADA	-0.877
VLYPO	-0.863
RAVN	-0.852
NETE	-0.84
MMSI	-0.837
NRIM	-0.836
MDLZ	-0.83

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Verve Therapeutics, Inc. 相关性 - 货币/商品

0.01
( neutral )

-0.31
( neutral )

0.00
( neutral )

0.16
( neutral )

0.12
( neutral )

-0.23
( neutral )

Verve Therapeutics, Inc. 财务报表

Annual	2023
营收:	$11.76M
毛利润:	$6.30M (53.61 %)
EPS:	$-3.12

FY	2023
营收:	$11.76M
毛利润:	$6.30M (53.61 %)
EPS:	$-3.12

FY	2022
营收:	$1.94M
毛利润:	$-4.77M (-245.75 %)
EPS:	$-2.91

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-6.78

Financial Reports:

No articles found.

Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.